Stay updated with breaking news from Ocular Surface. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today that the first patient has been enrolled in its Phase 3...
In support of the Hong Kong government’s new initiative, InnoHK Clusters, which aims to develop Hong Kong as a hub for global research collaboration
SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-ocular in Dry Eye Disease ProGIFT is a 3 arms, multicenter, randomized, double-masked clinical trial in Italy. CATANIA, Italy, April 27, 2021 /PRNewswire/ -- SIFI announced today the enrollment of the first patients in the ProGIFT trial (NCT04645446), which aims at evaluating the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with Dry Eye Disease (DED). ProGIFT (NCT04645446) is a multicenter, randomized, double-masked, placebo-controlled Phase II clinical trial comparing different concentration...
Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury Share Article A groundbreaking study from Neobiosis, a global expert in regenerative medicine, explains how a never-before-described process may open the door to regenerating damaged hearts. A peer-reviewed research paper from Dr. Ian White published in the journal Stem Cells and Regenerative Medicine explains how his studies of mouse hearts could be used to defeat a disease that kills 650,000 Americans each year. A revolutionary study may open the door to regenerating damaged hearts. We took a neonatal heart from a b...
Published: Feb 04, 2021 Consistent with Previously Announced Top-Line TRANQUILITY Run-In Cohort Results, Ocular Redness Selected as Primary Endpoint Tear RASP Levels Reduced After Single Doses of Reproxalap in Run-In Cohort of TRANQUILITY and Selected as Secondary Endpoint for Confirmation of Mechanism of Action LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced th...